Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol Nebulization in AHRF during HFNC
NCT06815679Phase 3Not yet recruiting
- Sponsor
- University of Ferrara
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of salbutamol in acute respiratory failure (ARF), pneumonia, sponsored by University of Ferrara. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
salbutamol
03
Conditions
acute respiratory failure (ARF)pneumonia
Beyond the preview
Go deeper on NCT06815679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815679.